Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 6, 2005, Pages 713-721

  Pittman, Phillip R ^a   Leitman, Susan F ^b   Barrera Oro, Julio G ^a   Norris, Sarah L ^a   Marano, Nina M ^c   Ranadive, Manmohan V ^a   Sink, Bonnie S ^b   McKee Jr , Kelly T ^a,d  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DynPort Vaccine Company LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIGEN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; TOXIN;

ADULT; ANIMAL CELL; ANTHRAX; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; MOUSE; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; SERODIAGNOSIS; VACCINATION;

ADULT; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PLASMAPHERESIS;

EID: 23844479255     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.6.713-721.2005     Document Type: Article

References (44)

1. Arnon, S. S., R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, S. Lillibridge, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, D. L. Swerdlow, K. Tonat, and the Working Group on Civilian Biodefense. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070.
2. Brunell, P. A., A. A. Gershon, W. T. Hughes, H. D. Riley, Jr., and J. Smith. 1972. Prevention of varicella in high risk children: a collaborative study. Pediatrics 50:18-22.
3. Burgin, M., G. Hopkins, B. Moore, J. Nasser, A. Richardson, and R. Minchinton. 1992. Serum IgG and IgM levels in new and regular long-term plasmapheresis donors. Med. Lab. Sci. 49:265-270.
4. Casadevall, A. 2002. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8:833-841.
5. Casadevall, A., and M. D. Scharff. 1995. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21:150-161.
6. Centers for Disease Control and Prevention. 1985. Diphtheria, tetanus, and pertussis: guidelines for vaccine prophylaxis and other preventive measures. Morb. Mortal. Wkly. Rep. 34:895-900.
7. Centers for Disease Control and Prevention. 2001. Investigation of bioterrorism-related anthrax: Connecticut, 2001. Morb. Mortal. Wkly. Rep. 50:1077-1079.
8. Ciszewski, T. S., S. Ralston, D. Acteson, S. Wasi, and S. J. Strong. 1993. Protein levels and plasmapheresis intensity. Transfus. Med. 3:59-65.
9. Dong, S. L. 1990. Progress in the control and research of anthrax in China. Salisbury Med. Bull. 68:104-105.
10. Ferry, B. J. 1976. The efficacy of vaccinial immune globulin. Vox Sang. 31:68-76.
11. Friedman, B. A., M. A. Schork, J. L. Mocniak, and H. A. Oberman. 1975. Short-term and long-term effects of plasmapheresis on serum proteins and immunoglobulins. Transfusion 15:467-472.
12. Gold, H. 1936. Studies on anthrax. Clinical report of ten human cases. J. Lab. Clin. Med. 4:134-152.
13. Henderson, D. W., S. Peacock, and F. C. Belton. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. 54:28-36.
14. Hering, D., W. Thompson, J. Hewetson, S. Little, S. Norris, and J. Pace-Templeton. 2004. Validation of the anthrax lethal toxin neutralization assay. Biologicals 1:17-27.
15. Hibbs, R. G., J. T. Weber, A. Corwin, B. M. Allos, M. S. Abd el Rehim, S. E. Sharkawy, J. E. Sarn, and K. T. McKee, Jr. 1996. Experience with the use of an investigational F(ab′)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin. Infect. Dis. 23:337-340.
16. Hodgson, A. E. 1928. The serum treatment of cutaneous anthrax. Lancet 215:594-595.
17. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, K. Tonat, and the Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon. 2002. Updated recommendations for management. JAMA 287:2236-2252.
18. Jernigan, D. B., P. L. Raghunathan, B. P. Bell, R. Brechner, E. A. Bresnitz, J. C. Butler, M. Cetron, M. Cohen, T. Doyle, M. Fischer, C. Greene, K. S. Griffith, J. Guarner, J. L. Hadler, J. A. Hayslett, R. Meyer, L. R. Petersen, M. Phillips, R. Pinner, T. Popovic, C. P. Quinn, J. Reefhuis, D. Reissman, N. Rosenstein, A. Schuchat, W. J. Shieh, L. Siegal, D. L. Swerdlow, F. C. Tenover, M. Traeger, J. W. Ward, I. Weisfuse, S. Wiersma, K. Yeskey, S. Zaki, D. A. Ashford, B. A. Perkins, S. Ostroff, J. Hughes, D. Fleming, J. P. Koplan, J. L. Gerberding, and the National Anthrax Epidemiologic Investigation Team. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028.
19. Knudson, G. B. 1986. Treatment of anthrax in man: history and current concepts. Mil. Med. 151:71-77.
20. Kobiler, D., Y. Gozes, H. Rosenberg, D. Marcus, S. Reuveny, and Z. Altboum. 2002. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70:544-550.
21. Lincoln, R. E., F. Klein, J. S. Walker, B. W. Haines, W. L. Jones, B. G. Mahlandt, and R. H. Friedman. 1965. Successful treatment of rhesus monkeys for septicemic anthrax. Antimicrob. Agents Chemother. 4:759-763.
22. Lincoln, R. E., J. S. Walker, F. Klein, and B. W. Haines. 1964. Anthrax. Adv. Vet. Sci. 9:327-368.
23. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175.
24. Little, S. F., B. E. Ivins, P. F. Fellows, M. L. M. Pitt, S. L. W. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430.
25. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthrads toxin. Infect. Immun. 56:1807-1813.
26. Little, S. F., S. H. Leppla, and A. M. Friedlander. 1990. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1606-1613.
27. Lockwood, C. B., and F. W. Andrewes. 1905. A case of anthrax successfully treated by Sclavo's serum. Br. Med. J. 1:16.
28. Lucchesi, P. 1932. Serum treatment of 19 cases of anthrax including one of external, internal and bacteremic type. Am. J. Med. Sci. 183:795-802.
29. Lucchesi, P. F., and N. Gildersleeve. 1941. The treatment of anthrax. JAMA 16:1506-1508.
30. Maiztegui, J. I., N. J. Fernandez, and A. J. De Damilano. 1979. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurologic syndrome. Lancet 2:1216-1217.
31. Maynard, J. A., C. B. Maassen, S. H. Leppla, K. Brasky, J. L. Patterson, B. L. Iverson, and G. Georgiou. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:597-601.
32. Moayeri, M., and S. H. Leppla. 2004. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 1:19-24.
33. Pitt, M. L. M., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
34. Pittman, P. R., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace-Templeton, R. Myers, G. W. Parker, and A. M. Friedlander. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20:1412-1420.
35. Quinn, C. P., P. M. Dull, V. Semenova, H. Li, S. Crotty, T. H. Taylor, E. Steward-Clark, K. L. Stamey, D. S. Schmidt, K. W. Stinson, A. E. Freeman, C. M. Elie, S. K. Martin, C. Greene, R. D. Aubert, J. Glidewell, B. A. Perkins, R. Ahmed, and D. S. Stephens. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis. 190:1228-1236.
36. Quinn, C. P., V. A. Semenova, C. M. Elie, S. Romero-Steiner, C. Greene, H. Li, K. Stamey, E. Steward-Clark, D. S. Schmidt, E. Mothershed, J. Pruckler, S. Schwartz, R. F. Benson, L. O. Helsel, P. F. Holder, S. E. Johnson, M. Kellum, T. Messmer, W. L. Thacker, L. Besser, B. D. Plikaytis, T. H. Taylor, Jr., A. E. Freeman, K. J. Wallace, P. Dull, J. Sejvar, E. Bruce, R. Moreno, A. Schuchat, J. R. Lingappa, S. K. Martin, J. Walls, M. Bronsdon, G. M. Carlone, M. Bajani-Ari, D. A. Ashford, D. S. Stephens, and B. A. Perkins. 2002. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg. Infect. Dis. 10:1103-1110.
37. Reed, E. C., R. A. Bowden, P. S. Dandliker, K. E. Lilleby, and J. D. Meyers. 1988. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109:783-788.
38. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferraan, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893.
39. Sawada-Hirai, R., I. Jiang, F. Wang, S. M. Sun, R. Nedellec, P. Ruther, A. Alvarez, D. Millis, P. R. Morrow, and A. S. Kang. 2004. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines 2:5.
40. Semenova, V. A., E. Steward-Clark, K. L. Stamey, T. H. Taylor, Jr., D. S. Schmidt, S. K. Martin, N. Marano, and C. P. Quinn. 2004. Mass value assignment of total and subclass-specific immunoglobulin G in a human standard anthrax reference serum. Clin. Diagn. Lab. Immunol. 11:919-923.
41. Szmuness, W., A. M. Prince, M. Goodman, C. Ehrich, R. Pick, and M. B. Ansari. 1974. Hepatitis B immune serum globulin in prevention of nonparenterally transmitted hepatitis. N. Engl. J. Med. 290:701-706.
42. Tacket, C. O., W. X. Shandera, J. M. Mann, N. T. Hargrett, and P. A. Blake. 1984. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am. J. Med. 76:794-798.
43. Tran-Mi, R., H. Stroch, K. Seidel, T. Schulzki, H. Haubelt, C. Anders, D. Nagel, K. E. Siegler, A. Vogt, D. Seller, and B. P. Hellstern. 2004. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang. 86:189-197.
44. Wild, M. A., H. Xin, T. Maruyama, M. J. Nolan, P. M. Calveley, J. D. Malone, M. R. Wallace, and K. S. Bowdish. 2003. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. 21:1305-1306.